Literature DB >> 21289611

Gout in 2010: progress and controversies in treatment.

Nicola Dalbeth1.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21289611     DOI： 10.1038/nrrheum.2010.222

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  8 in total

1.  Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study.

Authors:  Alexander So; Marc De Meulemeester; Andrey Pikhlak; A Eftal Yücel; Dominik Richard; Valda Murphy; Udayasankar Arulmani; Peter Sallstig; Naomi Schlesinger
Journal:  Arthritis Rheum       Date:  2010-10

2.  Incentives for drug development--the curious case of colchicine.

Authors:  Aaron S Kesselheim; Daniel H Solomon
Journal:  N Engl J Med       Date:  2010-04-14       Impact factor: 91.245

3.  High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study.

Authors:  Robert A Terkeltaub; Daniel E Furst; Katherine Bennett; Karin A Kook; R S Crockett; Matthew W Davis
Journal:  Arthritis Rheum       Date:  2010-04

4.  Does colchicine work? The results of the first controlled study in acute gout.

Authors:  M J Ahern; C Reid; T P Gordon; M McCredie; P M Brooks; M Jones
Journal:  Aust N Z J Med       Date:  1987-06

Review 5.  EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

Authors:  W Zhang; M Doherty; T Bardin; E Pascual; V Barskova; P Conaghan; J Gerster; J Jacobs; B Leeb; F Lioté; G McCarthy; P Netter; G Nuki; F Perez-Ruiz; A Pignone; J Pimentão; L Punzi; E Roddy; T Uhlig; I Zimmermann-Gòrska
Journal:  Ann Rheum Dis       Date:  2006-05-17       Impact factor: 19.103

6.  Gout-associated uric acid crystals activate the NALP3 inflammasome.

Authors:  Fabio Martinon; Virginie Pétrilli; Annick Mayor; Aubry Tardivel; Jürg Tschopp
Journal:  Nature       Date:  2006-01-11       Impact factor: 49.962

7.  Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.

Authors:  John S Sundy; Nancy J Ganson; Susan J Kelly; Edna L Scarlett; Claudia D Rehrig; William Huang; Michael S Hershfield
Journal:  Arthritis Rheum       Date:  2007-03

8.  Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo.

Authors:  Michael S Hershfield; L Jackson Roberts; Nancy J Ganson; Susan J Kelly; Ines Santisteban; Edna Scarlett; Denise Jaggers; John S Sundy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-26       Impact factor: 11.205
  8 in total
  3 in total

1.  Potential of vitamin C in the prevention and treatment of gout.

Authors:  Liang Shen; Hong-Fang Ji
Journal:  Nat Rev Rheumatol       Date:  2011-05-24       Impact factor: 20.543

2.  Contribution of mast cell-derived interleukin-1β to uric acid crystal-induced acute arthritis in mice.

Authors:  Laurent L Reber; Thomas Marichal; Jeremy Sokolove; Philipp Starkl; Nicolas Gaudenzio; Yoichiro Iwakura; Hajime Karasuyama; Lawrence B Schwartz; William H Robinson; Mindy Tsai; Stephen J Galli
Journal:  Arthritis Rheumatol       Date:  2014-10       Impact factor: 10.995

3.  The Role of NLR-related Protein 3 Inflammasome in Host Defense and Inflammatory Diseases.

Authors:  Chul-Su Yang; Dong-Min Shin; Eun-Kyeong Jo
Journal:  Int Neurourol J       Date:  2012-03-31       Impact factor: 2.835
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.